



Representative Legal Matters

Ian Chen

M&A / Foreign Direct Investment / Outbound Investment

- Acted for HK CTS Metropark Hotels, a wholly owned subsidiary of CTS Group, China's largest travel service provider, on its acquisition of all of the shares of Kew Green Hotels from TPG and Goldman Sachs. Kew Green Hotels owns 44 hotels and operates 11 hotels in U.K.. This deal is the largest ever acquisition of an European hotel group by a Chinese investor.
- Acted for Cristal, a titanium dioxide manufacturer in the Middle East on its acquisition of a PRC titanium product manufacturer.
- Acted for a PRC sovereign wealth fund and Haier in their investment or proposed investment in Sinopec Marketing Co., Ltd.
- Acted for BOCI on its direct investments in a storage and logistic business in PRC.
- Acted for Yunnan Chihong Zinc and Germanium Co. Ltd. in its CAD 100 million outbound joint venture with a Selwyn Resources Ltd., a publicly traded, Canadian base metals exploration and development company.
- Acted for Finet Group Limited in its acquisition of Hangzhou Tianchang Network Technology Company Limited, a China- Hangzhou-based internet game operator.
- Acted for Amgen Inc., one of the world's largest independent biotechnology companies in its joint venture with a PRC leading pharmaceutical company, Zhejiang Beta Pharma Co., Ltd.
- Acted for a leading integrated media and entertainment company in its strategic merger and acquisition of six PRC domestic advertisement companies engaged in designing, producing and brokering advertisement businesses.
- Acted for a leading international beverage company in its direct equity investment in two China domestic brewers.

Private Equity / Venture Capital

- Acted for Tencent for its investment in Koolearn, a leading online education service provider backed by New Oriental, for its pre-IPO restructuring.
- Acted for Gaw Capital for its acquisition of Guangzhou Damazhan Commercial Centre in China.

Baker McKenzie.

- Acted for Prudential for its Series C investment in, Prenetics, a Hong Kong based gene technology company engaging in the development and provision of genetic testing and digital health information services and solutions.
- Acted for Sunlife for its Series A investment in Timo, a Vietnam based insurtech company engaging in the development and provision of online platform for banking and insurance products.
- Acted for CMC on the formation of a PRC onshore PE fund and an offshore holding company to raise RMB10 billion to invest in media and culture industries.
- Acted for New Horizon and Raission Capital on their proposed investments in various sectors, including aerial device manufacturer and software outsourcing business in China.
- Acted for BOCI on its investments in a Guangzhou Baogong Investment Limited, which engages in storage and logistic business in China.
- Acted for China Culture Industrial Fund in its equity investments into a PRC advertising company.
- Acted for a PRC sovereign wealth fund in its proposed investment in Sinopec Marketing Co., Ltd.
- Acted for an online HR service provider in its Series A financing by Ceyuan Ventures.
- Acted for Haier in its purchase of preferred shares of an online video platform developer.
- Acted for Greenwoods Bloom Fund II, L.P. in its proposed Series C1 investment into a PRC-based online and mobile medical care consultation service provider.
- Acted for an online HR service provider in its Series A Financing by Ceyuan Ventures.
- Acted for 99 Bill, a Shanghai-based online payment settlement service company, in its Series E Preference Share financing.
- Acted for a Waterstone Pharmaceuticals, a Wuhan-based pharmaceutical company, in its Series B convertible note financing and the reincorporation of its Delaware holding Company.
- Acted for Chengwei Capital and several oversea private funds in the Series B preferred plus warrants investment in China Lodging Group, a now NASDAQ listed group company engaged in large hotel chain business.
- Acted for Baring Capital Asia in its preferred share investment in a BVI company that was engaged in the investment of natural gas, other energy and property projects.

Baker McKenzie.

- Acted for Barry Capital Asia in its investment in a Wangmin Changfu, a China- based company that was engaged in the Chinese medicine plantation and production.
- Acted for a Shanghai-based advertisement company in its multiple rounds of offshore financing from venture capital and private equity investors.
- Acted for an principal Asia private equity fund in its investment in multinational group companies that are engaged in anti-cancer pharmaceutical products development and manufacturing.

Fund Formation

- Acted for a leading PRC asset manager to sponsor a RMB denominated PE fund in Shenzhen Qianhai with a target total commitment of RMB 3 billion.
- Acted for a Chinese airport/airline group in its cooperation with an Australia based leading PE fund management company to sponsor a RMB-denominated fund with a size of RMB 5 billion.
- Acted for a leading Russian fund manager and a PRC asset manager to co-sponsor a foreign-invested partnership PE fund in Shenzhen Qianhai with a target total commitment of the RMB equivalent of USD 2 billion.